Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GEMP OTCMKTS:HBPCF OTCMKTS:NWPHF NASDAQ:SRRA NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMPGemphire Therapeutics$1.06-20.3%$4.97$0.24▼$1.49$15.76M2.82127,174 shs1.59 million shsHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$45.83M-0.05N/AN/ANWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/ASRRASierra Oncology$54.99$54.93$14.91▼$55.19$1.34B0.03931,731 shsN/ASVRASavara$3.60$2.98$1.89▼$4.70$622.21M0.561.67 million shs1.02 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMPGemphire Therapeutics-11.33%+96.17%+107.81%+90.00%-61.34%HBPCFHelix Biopharma0.00%0.00%0.00%0.00%-34.38%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SRRASierra Oncology0.00%0.00%0.00%0.00%0.00%SVRASavara-0.83%-6.01%+18.03%+73.91%-18.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMPGemphire Therapeutics$1.06-20.3%$4.97$0.24▼$1.49$15.76M2.82127,174 shs1.59 million shsHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$45.83M-0.05N/AN/ANWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/ASRRASierra Oncology$54.99$54.93$14.91▼$55.19$1.34B0.03931,731 shsN/ASVRASavara$3.60$2.98$1.89▼$4.70$622.21M0.561.67 million shs1.02 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMPGemphire Therapeutics-11.33%+96.17%+107.81%+90.00%-61.34%HBPCFHelix Biopharma0.00%0.00%0.00%0.00%-34.38%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SRRASierra Oncology0.00%0.00%0.00%0.00%0.00%SVRASavara-0.83%-6.01%+18.03%+73.91%-18.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGEMPGemphire Therapeutics 0.00N/AN/AN/AHBPCFHelix Biopharma 0.00N/AN/AN/ANWPHFNewron Pharmaceuticals 0.00N/AN/AN/ASRRASierra Oncology 0.00N/AN/AN/ASVRASavara 2.83Moderate Buy$7.50108.33% UpsideCurrent Analyst Ratings BreakdownLatest NWPHF, SRRA, GEMP, HBPCF, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/ANWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57SRRASierra Oncology$300K4,476.00N/AN/A$6.16 per share8.93SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AHBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-747.46%9/18/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/ASRRASierra Oncology-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/ASVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest NWPHF, SRRA, GEMP, HBPCF, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ASRRASierra OncologyN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGEMPGemphire TherapeuticsN/A0.670.67HBPCFHelix BiopharmaN/A0.420.42NWPHFNewron PharmaceuticalsN/AN/AN/ASRRASierra Oncology0.0221.2721.27SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGEMPGemphire Therapeutics17.53%HBPCFHelix BiopharmaN/ANWPHFNewron PharmaceuticalsN/ASRRASierra Oncology99.30%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipGEMPGemphire Therapeutics22.70%HBPCFHelix Biopharma7.60%NWPHFNewron PharmaceuticalsN/ASRRASierra Oncology44.10%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableHBPCFHelix Biopharma976.38 million70.57 millionNot OptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableSRRASierra Oncology10924.42 million13.65 millionOptionableSVRASavara20172.84 million163.63 millionOptionableNWPHF, SRRA, GEMP, HBPCF, and SVRA HeadlinesRecent News About These CompaniesFaruqi & Faruqi Reminds Savara Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA4 hours ago | prnewswire.comSavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRASeptember 18 at 4:44 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Savara, Inc. InvestorsSeptember 18 at 1:41 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRASeptember 18 at 10:00 AM | prnewswire.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Savara Inc. (SVRA)September 18 at 4:32 AM | theglobeandmail.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Savara Inc. (SVRA)September 18 at 4:32 AM | theglobeandmail.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 18 at 4:32 AM | prnewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraSeptember 17 at 10:11 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitSeptember 17 at 1:52 PM | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – SVRASeptember 17 at 12:29 PM | globenewswire.comDid You Lose Money in SVRA? Shareholders Who Lost Money in SVRA Should Contact Robbins LLP for Information About the Savara Inc. Securities Class Action LawsuitSeptember 16 at 8:52 PM | prnewswire.comSVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud LawsuitSeptember 16 at 8:01 PM | prnewswire.comRosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 16 at 6:00 PM | businesswire.comSavara Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights – SVRASeptember 16 at 5:18 PM | globenewswire.comKirby McInerney LLP Reminds Savara Inc. Investors of Class Action Filing and Encourages Investors to Contact the FirmSeptember 16 at 2:32 PM | globenewswire.comDeadline Approaching: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. SmithSeptember 16 at 2:22 PM | businesswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 16 at 12:00 PM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRASeptember 16 at 10:06 AM | theglobeandmail.comNovember 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRASeptember 16 at 8:45 AM | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRASeptember 15 at 3:50 PM | globenewswire.comSavara (NASDAQ:SVRA) Stock Price Down 3.3% - Should You Sell?September 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWPHF, SRRA, GEMP, HBPCF, and SVRA Company DescriptionsGemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Helix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 09/16/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 09/17/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.Sierra Oncology NASDAQ:SRRASierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.Savara NASDAQ:SVRA$3.60 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.60 0.00 (0.00%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
